TITLE

Insulin-like growth factor-1 signaling in renal cell carcinoma

AUTHOR(S)
Tracz, Adam F.; Szczylik, Cezary; Porta, Camillo; Czarnecka, Anna M.
PUB. DATE
July 2016
SOURCE
BMC Cancer;7/12/2016, Vol. 16, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Renal cell carcinoma (RCC) incidence is highest in highly developed countries and it is the seventh most common neoplasm diagnosed. RCC management include nephrectomy and targeted therapies. Type 1 insulin-like growth factor (IGF-1) pathway plays an important role in cell proliferation and apoptosis resistance. IGF-1 and insulin share overlapping downstream signaling pathways in normal and cancer cells. IGF-1 receptor (IGF1R) stimulation may promote malignant transformation promoting cell proliferation, dedifferentiation and inhibiting apoptosis. Clear cell renal cell carcinoma (ccRCC) patients with IGF1R overexpression have 70 % increased risk of death compared to patients who had tumors without IGF1R expression. IGF1R signaling deregulation may results in p53, WT, BRCA1, VHL loss of function. RCC cells with high expression of IGF1R are more resistant to chemotherapy than cells with low expression. Silencing of IGF1R increase the chemosensitivity of ccRCC cells and the effect is greater in VHL mutated cells. Understanding the role of IGF-1 signaling pathway in RCC may result in development of new targeted therapeutic interventions. First preclinical attempts with anti-IGF-1R monoclonal antibodies or fragment antigen-binding (Fab) fragments alone or in combination with an mTOR inhibitor were shown to inhibit in vitro growth and reduced the number of colonies formed by of RCC cells.
ACCESSION #
116833434

 

Related Articles

  • Insulin Receptor Expression in Clear Cell Renal Cell Carcinoma and Its Relation to Prognosis. Lkhagvadorj, Sayamaa; Sung Soo Oh; Mi-Ra Lee; Jae Hung Jung; Hyun Chul Chung; Seung-Kuy Cha; Minseob Eom // Yonsei Medical Journal;Jun2014, Vol. 55 Issue 4, p861 

    Purpose: Both insulin and insulin-like growth factor (IGF)-1 signaling are key regulators of energy metabolism, cellular growth, proliferation, and survival. The IGF-1 receptor (IGF-1R) is overexpressed in most types of human cancers including renal cell carcinoma (RCC) with poor prognosis....

  • The mTOR Pathway: A New Target in Cancer Therapy. Ciuffreda, L.; Di Sanza, C.; Incani, U. C.; Milella, M. // Current Cancer Drug Targets;Aug2010, Vol. 10 Issue 5, p484 

    No abstract available.

  • Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors. George, Saby; Shah, Shetal N.; Bukowski, Ronald M. // Reviews on Recent Clinical Trials;May2010, Vol. 5 Issue 2, p117 

    Malignant solid tumors have been traditionally treated utilizing cytotoxic chemotherapies, which work against rapidly multiplying tumors. The current response evaluation in solid tumor is based on the Response Evaluation Criteria in Solid Tumors (RECIST). This method relies mainly on...

  • Insulin Receptor Expression in Clear Cell Renal Cell Carcinoma and Its Relation to Prognosis. Lkhagvadorj, Sayamaa; Sung Soo Oh; Mi-Ra Lee; Jae Hung Jung; Hyun Chul Chung; Seung-Kuy Cha; Minseob Eom // Yonsei Medical Journal;Jul2014, Vol. 55 Issue 4, p861 

    Purpose: Both insulin and insulin-like growth factor (IGF)-1 signaling are key regulators of energy metabolism, cellular growth, proliferation, and survival. The IGF-1 receptor (IGF-1R) is overexpressed in most types of human cancers including renal cell carcinoma (RCC) with poor prognosis....

  • PGE2 promotes renal carcinoma cell invasion through activated RalA. Li, Z; Zhang, Y; Kim, W J; Daaka, Y // Oncogene;3/14/2013, Vol. 32 Issue 11, p1408 

    Incidence of kidney cancer is on the rise, and a better understanding of molecular mechanisms involved in the cancer invasion and metastasis is required for the development of curative therapeutics. In this study, we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the...

  • mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. Bailey, Sean T.; Zhou, Bing; Damrauer, Jeffrey S.; Krishnan, Bhavani; Wilson, Harper L.; Smith, Aleisha M.; Li, Mingqing; Yeh, Jen Jen; Kim, William Y. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus...

  • Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer. D'Alterio, C.; Consales, C.; Polimeno, M.; Franco, R.; Cindolo, L.; Portella, L.; Cioffi, M.; Calemma, R.; Marra, L.; Claudio, L.; Perdonà, S.; Pignata, S.; Facchini, G.; Longo, N.; Pucci, L.; Ottaiano, A.; Costantini, S.; Castello, G.; Scala, S.; Cartenì, G. // Current Cancer Drug Targets;Nov2010, Vol. 10 Issue 7, p772 

    No abstract available.

  • Proteomic Analysis of Signaling Network Regulation in Renal Cell Carcinomas with Differential Hypoxia-Inducible Factor-2α Expression. Nagaprashantha, Lokesh Dalasanur; Talamantes, Tatjana; Singhal, Jyotsana; Guo, Jia; Vatsyayan, Rit; Rauniyar, Navin; Awasthi, Sanjay; Singhal, Sharad S.; Prokai, Laszlo // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: The loss of von Hippel–Lindau (VHL) protein function leads to highly vascular renal tumors characterized by an aggressive course of disease and refractoriness to chemotherapy and radiotherapy. Loss of VHL in renal tumors also differs from tumors of other organs in that the...

  • Laparoscopic Partial Nephrectomy: Expanding Role in the Treatment of Localized Renal Cell Carcinoma. Abdellateef, Mohamed // World Journal of Laparoscopic Surgery;Sep-Dec2011, Vol. 4 Issue 3, p169 

    Context: The increasing incidence of localized renal cell carcinoma (RCC) over the last three decades have been well evident and have called for different treatment modalities among which laparoscopic partial nephrectomy has evolved. Objective: To review the development, techniques, outcomes and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics